RAC - Charts & Price Action, page-19335

If you take another look at the November strategy update you will see RAC is positioning to achieve accelerated approval (i.e. approval from Phase 2). I can’t emphasise enough for everyone to study G1 therapeutics and their path to market.

I do agree that RAC has faced some macro headwinds just like the entire sector, but until Feb 2023 we were going pretty well with a SP above $2.25. The collapse of the SP to 74c in August 2023 was entirely self inflicted. The recent SP weakness is driven by a combination of a slow news period as we transition from RC110 to RC220 combined with some less than helpful selling from a single individual.

The good news is none of this will have any impact on the company by the end of the year. What will matter is accomplishing what we have promised.